Krystal Files Application to Start Clinical Trial of Gene Therapy Candidate KB103 – Epidermolysis Bullosa News
Epidermolysis Bullosa News |
Krystal Files Application to Start Clinical Trial of Gene Therapy Candidate KB103
Epidermolysis Bullosa News Krystal Biotech has submitted an investigational new drug application with the U.S. Food and Drug Administration (FDA) to start a Phase 1/2 clinical trial of its lead gene therapy candidate KB103 for the treatment of dystrophic epidermolysis bullosa … Gene Therapy May Boost Stroke Recovery |
